Não-adesão à terapêutica medicamentosa do glaucoma

Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma

“…Therefore, this study showed that the efficacy of latanoprostene bunod was comparatively higher than latanoprost and timolol, with latanoprostene bunod reaching the target of ≤17.5 mmHg ( 14 ). The results of the study were consistent with previous randomized, double-blinded studies ( 1 , 6 ) and a preclinical study ( 12 ). Pharmacological therapies in open-angle glaucoma include PG analogs or β -blockers ( 15 ).…”

“…This study reported higher ocular adverse events for latanoprostene bunods than for timolol. The ocular adverse events were comparable to those of the randomized, double-blinded studies ( 1 , 6 ) and randomized crossover clinical trial ( 17 ). Further research is required to decrease ocular adverse effects related to latanoprostene bunod treatment in open-angle glaucoma.…”

“…The ultimate goal of glaucoma treatment is to slow down disease progression to a rate in which the patient will not experience a vision-related decrease in quality of life ( 5 , 6 ). Glaucoma treatment in developing countries should consider clinical, laser, and surgical approaches.…”

“…Glaucoma medications do not improve vision, may have important side effects, and are relatively expensive. Thus, compliance can be a major issue, which is related to the level of education and socio-economic status of the patient ( 5 , 6 ).…”

Managing glaucoma in developing countries

“…Thus, compliance can be a major issue, which is related to level of education and socio-economic status of the patient. 16 19 In a recent study conducted in Brazil, 21.5% of the patients revealed non-adherence to treatment. Currently, some centers are receiving government support in Brazil to provide medications for glaucoma patients at no cost.…”